Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice

D. J. Buurman*, J. M. Maurer, R. J. Keizer, J. G. W. Kosterink, G. Dijkstra

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

61 Citations (Scopus)
69 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science